Q-omics provides the consensus-scored ERG28 profile across patient tissues and cancer cell-line models. ERG28 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, ERG28 is differentially expressed in 12, with the highest sampling consensus in KIRC. Additionally, ERG28 RNA expression shows 18,381 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight HNSC, KIRC, and ACC as cancer lineages where ERG28 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ERG28 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ERG28 survival associations across molecular data types. ERG28 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (1) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ERG28 RNA expression–survival associations across cancer types. High ERG28 expression shows unfavorable associations in HNSC, ACC, LAML and CHOL, but favorable associations in BRCA and KIRC. The HNSC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for ERG28 RNA expression.
This table summarizes ERG28 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 4. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for ERG28. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ERG28 shows lower tumor expression in KIRC and higher tumor expression in BLCA, COAD, HNSC, UCEC and BRCA. The KIRC box plot shows higher ERG28 RNA expression in normal versus tumor tissue (log2 FC = −0.670, t-test p < 0.001).
This table shows molecular features associated with ERG28 in patient tissues and cancer cell lines. In patient samples, ERG28 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, ERG28 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in BREAST and BLOOD_Lymphoma.
